Theranexus (ALTHX.PA) Stock Price
Theranexus Price
Revenue has compounded at 16.9% per year over the past 9 years to 2.28 M EUR. Theranexus's net margin stands at -77.3%, up from -1,628.5% several years earlier. Analysts set a median price target of 4.49 EUR, implying 32.0% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
Theranexus stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Theranexus business model & stock analysis
Frequently asked questions about Theranexus
The business model of Theranexus SA revolves around the development and commercialization of innovative therapeutic solutions for neurological disorders. As a biopharmaceutical company, Theranexus specializes in the research and creation of drug candidates that target the brain's interactions between neurons and glial cells. By focusing on modulating the activity of these cells, Theranexus aims to develop treatments that can address a wide range of neurological conditions such as neurodegenerative diseases and psychiatric disorders. Through its unique approach and partnerships with leading research institutions, Theranexus is dedicated to improving the lives of patients by providing effective and safe therapeutic options.
Theranexus SA primarily operates in the pharmaceutical and biotechnology industries.
The main competitors of Theranexus SA in the market include other companies operating in the biotechnology and pharmaceutical sectors. These competitors may include companies such as XYZ Pharmaceuticals, ABC Biotech, and LMN Therapeutics.
Theranexus SA is a French biopharmaceutical company that specializes in the development of drug candidates for central nervous system disorders. Established in 2013, Theranexus focuses on the research and discovery of innovative therapeutic solutions. With a team of experienced scientists and researchers, the company aims to address major therapeutic challenges in neurological disorders such as Alzheimer's disease and Parkinson's disease. Theranexus leverages its proprietary technology, the Theranexus Target Binding Platform, to enhance the efficacy and safety profiles of existing drugs. By harnessing synergies between drugs, the company aims to improve patient outcomes and provide novel treatment solutions for neurological conditions.
Theranexus SA, a prominent pharmaceutical company, has achieved several significant milestones. A major accomplishment for Theranexus SA was the successful completion of a Phase 2 clinical trial for its lead product, THN102, which demonstrated promising results for treating Parkinson's disease. Furthermore, Theranexus SA collaborated with leading research institutions and pharmaceutical partners to develop innovative therapies for various neurological disorders. The company's dedication to research and development has resulted in the advancement of novel drug candidates and the initiation of multiple clinical trials. The achievements of Theranexus SA signify its commitment to revolutionizing treatment options for patients suffering from neurological conditions.
Theranexus SA, a leading pharmaceutical company, primarily operates in France and Europe. With its headquarters in Lyon, France, Theranexus is a key player in the neuropharmaceutical industry. The company's presence expands across various regions, including the European Union (EU), with special emphasis on countries like Germany, the United Kingdom, and Spain. Theranexus also focuses on bolstering its global footprint, collaborating with partners worldwide to ensure widespread availability and accessibility of its innovative therapies. This commitment to international presence fuels Theranexus' mission to deliver cutting-edge solutions for neurological disorders to patients across the globe.
Theranexus SA represents a strong set of values and corporate philosophy. The company focuses on innovation and leveraging cutting-edge science to develop novel therapeutic solutions. Theranexus SA believes in embracing collaboration and partnerships to expedite the development and commercialization of their products. With a commitment to patient-centric care, Theranexus SA aims to improve the lives of individuals through their innovative treatments. The company prioritizes scientific rigor, ethics, and transparency in all aspects of their operations. By combining expertise in neuroscience, pharmacology, and technology, Theranexus SA strives to deliver effective and safe solutions to address unmet medical needs.
Analysts currently set an average price target of 4.49 EUR for the Theranexus stock (median: 4.49 EUR), implying +32.0 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Theranexus stock: 8 recommend buying, 1 holding and 0 selling.
The Theranexus share (ALTHX.PA) is listed on 4 stock exchanges, including: Frankfurt (3VG.F), München (3VG.MU), Paris (ALTHX.PA).
Theranexus SA is a leading biopharmaceutical company focused on the development of innovative therapies for the central nervous system (CNS). The company's business model involves creating a platform for drug discovery and development of candidate drugs for neurology, psychiatry, and other CNS disorders. Theranexus SA collaborates closely with a network of leading researchers in the field of neurology and psychiatry to develop and market groundbreaking therapies. The company works with academic institutions and pharmaceutical companies to advance its research and gather expertise in various areas of neuroscience. Theranexus SA utilizes novel technologies, particularly its SynapCell platform, to improve the effectiveness and safety of medications. The company currently has several product candidates in various stages of clinical development, including treatments for Parkinson's disease-related sleep disorders, depression, epilepsy, and Alzheimer's disease. In addition to its product candidates, Theranexus SA offers services such as neurology and psychiatry consulting, biomarker development and validation, drug effect and toxicity analysis, and intellectual property management in the field of neuroscience. Overall, Theranexus SA is an innovative company positioned for success in expanding its business with its range of promising product candidates and a wide range of services.
The revenue cannot currently be calculated for Theranexus.
The expected profit of Theranexus is 1.66 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Theranexus is currently 28.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Theranexus stock.
The P/S cannot be calculated for Theranexus currently.
The Eulerpool Quality Score for Theranexus is 4/10.
The ISIN of Theranexus is FR0013286259. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Theranexus is A2H6LX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Theranexus is ALTHX.PA. The ticker symbol is used to trade Theranexus shares on the stock exchange.
Theranexus stock
Theranexus Peer Group
Theranexus Ticker
Theranexus FIGI
All fundamentals and in-depth analysis of Theranexus
Our stock analysis for Theranexus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theranexus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.